OBJECTIVE: To investigate whether adenosine diphosphate (ADP)-derived adenosine might inhibit platelet aggregation, especially in the presence of a P2Y₁₂ antagonist, where the effects of ADP at the P2Y₁₂ receptor would be prevented. METHODS AND RESULTS: Platelet aggregation was measured in response to thrombin receptor activator peptide by platelet counting in platelet-rich plasma (PRP) and whole blood in the presence of ADP and the P2Y₁₂ antagonists cangrelor, prasugrel active metabolite, and ticagrelor. In the presence of a P2Y₁₂ antagonist, preincubation of PRP with ADP inhibited aggregation; this effect was abolished by adenosine deaminase. No inhibition of aggregation occurred in whole blood except when dipyridamole was added to inhibit adenosine uptake into erythrocytes. The effects of ADP in PRP and whole blood were replicated using adenosine and were directly related to changes in cAMP (assessed by vasodilator-stimulated phosphoprotein phosphorylation). All results were the same irrespective of the P2Y₁₂ antagonist used. CONCLUSIONS: ADP inhibits platelet aggregation in the presence of a P2Y₁₂ antagonist through conversion to adenosine. Inhibition occurs in PRP but not in whole blood except when adenosine uptake is inhibited. None of the P2Y₁₂ antagonists studied replicated the effects of dipyridamole in the experiments that were performed.
OBJECTIVE: To investigate whether adenosine diphosphate (ADP)-derived adenosine might inhibit platelet aggregation, especially in the presence of a P2Y₁₂ antagonist, where the effects of ADP at the P2Y₁₂ receptor would be prevented. METHODS AND RESULTS:Platelet aggregation was measured in response to thrombin receptor activator peptide by platelet counting in platelet-rich plasma (PRP) and whole blood in the presence of ADP and the P2Y₁₂ antagonists cangrelor, prasugrel active metabolite, and ticagrelor. In the presence of a P2Y₁₂ antagonist, preincubation of PRP with ADP inhibited aggregation; this effect was abolished by adenosine deaminase. No inhibition of aggregation occurred in whole blood except when dipyridamole was added to inhibit adenosine uptake into erythrocytes. The effects of ADP in PRP and whole blood were replicated using adenosine and were directly related to changes in cAMP (assessed by vasodilator-stimulated phosphoprotein phosphorylation). All results were the same irrespective of the P2Y₁₂ antagonist used. CONCLUSIONS:ADP inhibits platelet aggregation in the presence of a P2Y₁₂ antagonist through conversion to adenosine. Inhibition occurs in PRP but not in whole blood except when adenosine uptake is inhibited. None of the P2Y₁₂ antagonists studied replicated the effects of dipyridamole in the experiments that were performed.
Authors: Zachary M Huttinger; Michael W Milks; Michael S Nickoli; William L Aurand; Lawrence C Long; Debra G Wheeler; Karen M Dwyer; Anthony J F d'Apice; Simon C Robson; Peter J Cowan; Richard J Gumina Journal: Am J Pathol Date: 2012-05-18 Impact factor: 4.307
Authors: Jingyuan Fan; Yongshu Zhang; Olivia N Chuang-Smith; Kristi L Frank; Brian D Guenther; Marissa Kern; Patrick M Schlievert; Mark C Herzberg Journal: PLoS One Date: 2012-06-07 Impact factor: 3.240
Authors: Michael N Sayegh; Kimberly A Cooney; Woojin M Han; Lanfang Wang; Frederick Strobel; Laura M Hansen; Andrés J García; Rebecca D Levit Journal: Arterioscler Thromb Vasc Biol Date: 2021-04-22 Impact factor: 10.514
Authors: L M Yerges-Armstrong; S Ellero-Simatos; A Georgiades; H Zhu; J P Lewis; R B Horenstein; A L Beitelshees; A Dane; T Reijmers; T Hankemeier; O Fiehn; A R Shuldiner; R Kaddurah-Daouk Journal: Clin Pharmacol Ther Date: 2013-06-11 Impact factor: 6.875
Authors: Paul C J Armstrong; Nicholas S Kirkby; Melissa V Chan; Michaela Finsterbusch; Nancy Hogg; Sussan Nourshargh; Timothy D Warner Journal: Blood Date: 2015-07-27 Impact factor: 22.113